Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Garfall, Alfred L., Maus, Marcela V., Hwang, Wei-Ting, Lacey, Simon F., Mahnke, Yolanda D., Melenhorst, J. Joseph, Zheng, Zhaohui, Vogl, Dan T., Cohen, Adam D., Weiss, Brendan M., Dengel, Karen, Kerr, Naseem D.S., Bagg, Adam, Levine, Bruce L., June, Carl H., Stadtmauer, Edward A.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4646711/
https://ncbi.nlm.nih.gov/pubmed/26352815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1504542
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars